Search
Research
Clinical development strategy for a candidate group A streptococcal vaccineThis review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin
Research
Modes of transmission and attack rates of group A Streptococcal infection: a protocol for a systematic review and meta-analysisSummarising the current knowledge of Strep A transmission to humans will address gaps in the evidence and inform prevention and control strategies. The objective of this study is to evaluate the modes of transmission and attack rates of group A streptococcal infection in human populations.
Research
Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelinesSystematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations
Research
Long-term outcomes from acute rheumatic fever and rheumatic heart disease: A Data-Linkage and Survival Analysis ApproachAdverse outcomes for people with acute rheumatic fever and rheumatic heart disease and the effect of comorbidities and demographic factors on these outcomes
Research
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk indigenous infants (PREV-IX-COMBO)Otitis media (OM) starts within weeks of birth in almost all Indigenous infants living in remote areas of the Northern Territory (NT).
Research
Burden of rheumatic heart disease (RHD) and impact of prevention strategies: comprehensive evidence to drive the RHD EndgameThis project will use a multi-jurisdictional linked RHD dataset to establish a baseline burden of RHD in Australia to allow for monitoring the impact of burden over time, and to form the basis of clearly defined targets for the END RHD CRE Endgame Strategy.
Research
Reach: to stop rheumatic heart diseaseReach works to promote the health of vulnerable populations by providing technical support to local, regional and global efforts to prevent and control rheumatic fever and rheumatic heart disease (RF/RHD).
Research
The END RHD CRE: Developing an end game for rheumatic heart disease in AustraliaThe END RHD CRE will undertake a number of projects across several disciplines of research including epidemiology, biomedical sciences; implementation and translation; and understanding the RHD community with a special focus on documenting the experiences of those living with the disease.
Research
Streptococcus pyogenes pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infectionsKnowledge gaps regarding human immunity to Streptococcus pyogenes have impeded vaccine development. To address these gaps and evaluate vaccine candidates, we established a human challenge model of S. pyogenes pharyngitis. Here, we analyse antibody responses in serum and saliva against 19 antigens to identify characteristics distinguishing 19 participants who developed pharyngitis and 6 who did not.